biostudies-literatureSimpson ELNCATS NIH HHSEli Lilly and Company531-538https://www.ebi.ac.uk/biostudies/studies/S-EPMC9804170biostudies-literatureUnknown187(4)<h4>Background</h4>The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) is a standardized severity assessment for use in clinical trials and registries for atopic dermatitis (AD).<h4>Objectives</h4>To investigate the reliability, validity, responsiveness and within-patient meaningful change of the vIGA-AD.<h4>Methods</h4>Data were analysed from adult patients with moderate-to-severe AD in the BREEZE-AD1 (N = 624 patients; NCT03334396), BREEZE-AD2 (N = 615; NCT03334422) and BREEZE-AD5 (N = 440; NCT03435081) phase III baricitinib clinical studies.<h4>Results</h4>Across studies, test-retest reliability for stable patients showed moderate-to-good agreement [range of Kappa values for Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD), 0·516-0·639; for EcThe British journal of dermatologyThe Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.PMC9804170N/AUL1 TR001863Paller ASSun LBissonnette REichenfield LFReich KThyssen JPNunes FPSimpson ELDeLozier AMDoll HKing BSilverberg JIfalseThe Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.<h4>Background</h4>The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) is a standardized severity assessment for use in clinical trials and registries for atopic dermatitis (AD).<h4>Objectives</h4>To investigate the reliability, validity, responsiveness and within-patient meaningful change of the vIGA-AD.<h4>Methods</h4>Data were analysed from adult patients with moderate-to-severe AD in the BREEZE-AD1 (N = 624 patients; NCT03334396), BREEZE-AD2 (N = 615; NCT03334422) and BREEZE-AD5 (N = 440; NCT03435081) phase III baricitinib clinical studies.<h4>Results</h4>Across studies, test-retest reliability for stable patients showed moderate-to-good agreement [range of Kappa values for Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD), 0·516-0·639; for Ec2022-01-01T00:00:00Z2022 Oct2026-05-28T06:20:47.832Z2025-04-06T09:02:56.317ZS-EPMC98041703544253010.1111/bjd.21615